Don’t Miss This Adverse Drug Reaction When Tapering Benzodiazepines

The Adverse Reaction That Can Hide Behind “Anxiety”

Akathisia is a neuropsychiatric movement disorder with both subjective and observable features. Internally, a person may describe unbearable restlessness, nervous energy, tension, crawling sensations, or a feeling of being driven out of their own skin. Externally, family members or clinicians may notice repetitive movement.

Common signs of akathisia include:

• Pacing for long periods without a practical reason
• Rocking while sitting or standing
• Marching in place or shifting weight from foot to foot
• Constantly swinging, crossing, or uncrossing the legs
• Feeling unable to sit through a meal, appointment, or television program
• Experiencing mounting distress when movement is restricted
• Getting little or no emotional relief from reassurance

The movement is not simply a habit or ordinary fidgeting. The person generally moves because remaining still feels intolerable. Movement may provide brief partial relief, but it often fails to remove the internal sensation completely.

Akathisia is most widely associated with antipsychotic medications, although antidepressants, anti-nausea drugs, and several other medication classes may also trigger it. Withdrawal akathisia can emerge after a drug dose is reduced or discontinued. Current benzodiazepine tapering guidance includes akathisia and severe restlessness among possible withdrawal manifestations.

Why Benzodiazepine Withdrawal Can Produce Severe Restlessness

Benzodiazepines such as alprazolam, clonazepam, diazepam, lorazepam, and temazepam enhance signaling through gamma-aminobutyric acid, commonly called GABA. GABA helps reduce excessive neuronal activity and supports calmness, sleep, muscle relaxation, and seizure control.

With regular exposure, the nervous system adapts to the medication. Physical dependence can develop even when a person takes the drug exactly as prescribed. Physical dependence is not automatically the same as addiction. It means the body has adjusted to the medicine and may react when the dose is reduced too quickly.

During withdrawal, inhibitory signaling may temporarily become inadequate relative to excitatory activity. The result can be a hyperaroused nervous system. Symptoms may include insomnia, tremors, muscle twitching, palpitations, sweating, sensory hypersensitivity, panic, perceptual changes, and abnormal restlessness.

No single mechanism fully explains benzodiazepine-withdrawal akathisia. The biology of akathisia itself remains incompletely understood. Changes involving GABA, dopamine, serotonin, stress pathways, and motor-control circuits may all contribute. What matters clinically is the timing: a new, intense urge to move that appears after a dose reduction should not automatically be dismissed as ordinary anxiety.

Akathisia Versus Anxiety: How Can You Tell the Difference?

Anxiety and akathisia can overlap. Both may involve tension, insomnia, racing thoughts, palpitations, and a sense that something is terribly wrong. Akathisia may also generate secondary anxiety because the physical sensation is frightening.

The most useful distinction is the compulsion to move. Anxiety is commonly organized around fear, worry, anticipation, or intrusive thoughts. Akathisia is more strongly characterized by an internally driven inability to remain still.

Questions that may help clarify the symptoms

• Do you feel physically compelled to move, even when your thoughts are relatively calm?
• Does sitting still make the distress rapidly worse?
• Are you pacing, rocking, or moving your legs repeatedly?
• Did the symptoms appear or intensify after a medication reduction?
• Did you recently begin, stop, or change another psychiatric or anti-nausea medication?
• Does movement provide temporary relief without solving the underlying sensation?

A clinician may use a structured instrument such as the Barnes Akathisia Rating Scale to assess observable movement, subjective restlessness, distress, and overall severity. A rating scale does not replace clinical judgment, but it can prevent a vague complaint such as “I feel agitated” from disappearing into the medical-record wilderness.

Other Conditions That Can Look Similar

Restless legs syndrome

Restless legs syndrome often causes uncomfortable leg sensations that become worse during rest, particularly in the evening or at night. Walking may bring meaningful relief. Akathisia may involve the entire body, persist throughout the day, and produce a more generalized sense of internal torment.

Agitation

Agitation may involve irritability, emotional upset, shouting, impulsive behavior, or goal-directed activity. Akathisia can exist without anger or a specific emotional trigger. A person may be mentally exhausted yet physically unable to stop moving.

Mania or hypomania

Mania usually includes additional features such as elevated or unusually irritable mood, accelerated speech, increased confidence, impulsive decisions, and a reduced perceived need for sleep. Someone with akathisia may desperately want to sleep but be unable to settle physically.

Medication-induced activation

Antidepressants, antipsychotics, stimulants, anti-nausea drugs, and other medications can cause activation or akathisia. A complete medication review is therefore essential. The benzodiazepine taper may be part of the story without being the only character in the cast.

General benzodiazepine withdrawal

Withdrawal itself can cause ordinary agitation and anxiety without meeting the clinical description of akathisia. The distinction is not always neat. Symptoms may overlap, change from hour to hour, or appear together.

Why Akathisia Is Sometimes Missed During a Benzodiazepine Taper

Several factors make this adverse drug reaction easy to overlook. First, many patients originally received benzodiazepines for anxiety or insomnia. When those symptoms worsen during a taper, recurrence of the original disorder may seem like the obvious explanation.

Second, akathisia is often associated in medical training with antipsychotic medications. Clinicians who do not routinely manage movement disorders may not immediately consider withdrawal akathisia.

Third, patients may struggle to describe the sensation. Phrases such as “I’m crawling inside,” “I can’t get comfortable,” or “my body won’t let me stop” can sound metaphorical. They may actually be valuable diagnostic clues.

Finally, the reaction may not appear immediately. Shorter-acting benzodiazepines can produce withdrawal symptoms relatively soon after a dose reduction, whereas changes involving longer-acting drugs may take several days to become obvious. Some symptoms also wax and wane rather than following a tidy, predictable timeline.

What to Do When Severe Restlessness Appears

A person who develops possible akathisia during benzodiazepine tapering should contact the prescribing clinician promptly. It is useful to report the exact dose changes, dates, medication schedule, movement pattern, sleep disruption, and any recently added or discontinued drugs.

Do not abruptly stop the benzodiazepine

Sudden discontinuation or a rapid dose reduction can trigger dangerous withdrawal reactions, including seizures, delirium, hallucinations, psychosis, and severe autonomic instability. The U.S. Food and Drug Administration requires benzodiazepines to carry prominent warnings about physical dependence and withdrawal and advises gradual tapering.

Do not make large corrective dose changes alone

It may be tempting to skip doses, double a dose, restart an old dose, or improvise an alternating-day schedule. These changes can produce unstable drug concentrations and make the clinical picture harder to interpret. Dose adjustments should be discussed with the prescriber whenever possible.

Ask whether the taper should be paused or slowed

Current multidisciplinary guidance generally recommends starting with individualized reductions of approximately 5% to 10% every two to four weeks. The taper typically should not exceed a 25% reduction every two weeks. People with strong physical dependence, previous withdrawal problems, or severe emerging symptoms may require smaller reductions, longer holding periods, or a substantially slower schedule.

These percentages are general clinical guidance, not a do-it-yourself prescription. Tablet strengths, liquid formulations, liver function, age, medication half-life, other prescriptions, and seizure risk can change the safest approach.

Review all medications and substances

A clinician should know about prescription drugs, over-the-counter sleep products, antihistamines, supplements, caffeine, alcohol, cannabis, opioids, and non-prescribed substances. Alcohol and other central nervous system depressants are not safe home remedies for benzodiazepine withdrawal. Combining benzodiazepines with opioids can also cause profound sedation and life-threatening respiratory depression.

Use supportive treatment carefully

Cognitive behavioral therapy, cognitive behavioral therapy for insomnia, sleep scheduling, reassurance, and regular follow-up can support a taper. Evidence for medications used specifically to treat benzodiazepine-withdrawal symptoms remains limited and mixed. Treatments sometimes used for antipsychotic-induced akathisia cannot automatically be assumed to work safely in every withdrawal case.

When Akathisia or Withdrawal Becomes an Emergency

Severe akathisia can be psychologically overwhelming. Immediate help is warranted when restlessness is accompanied by thoughts of suicide, self-harm, aggression, inability to remain safe, or a feeling that the distress is becoming uncontrollable.

Emergency medical evaluation is also necessary for:

• A seizure or seizure-like activity
• Severe confusion, delirium, or loss of contact with reality
• Hallucinations or extreme paranoia
• Fainting, chest pain, or marked cardiovascular symptoms
• Severe vomiting, dehydration, or inability to take medication safely
• Slowed or difficult breathing, especially when opioids or alcohol are involved
• Any immediate risk of self-harm or harm to another person

In these situations, call 911 or seek emergency care. A complicated benzodiazepine withdrawal syndrome may require inpatient management rather than another outpatient appointment several weeks away.

Can Withdrawal Symptoms Continue After the Taper Ends?

Many people improve as the taper is slowed, completed, or adjusted. However, a subset of patients reports symptoms that persist beyond the expected acute withdrawal period. These may include sleep disturbance, tinnitus, sensory symptoms, cognitive difficulty, involuntary movement, depersonalization, and akathisia.

The frequency, mechanisms, and ideal treatment of prolonged symptoms are still being studied. Persistent symptoms do not necessarily mean the original psychiatric condition has returned, nor do they prove that every new symptom is caused by withdrawal. Careful evaluation is required to rule out neurological, metabolic, medication-related, and psychiatric explanations.

Recovery may also be nonlinear. A person can have several better days followed by a difficult period without necessarily losing all previous progress. The nervous system is apparently not interested in providing weekly performance charts.

How Patients Can Prepare for a Safer Benzodiazepine Taper

Preparation does not guarantee a symptom-free taper, but it can make complications easier to identify and manage.

• Confirm who will supervise the taper and how urgent concerns should be reported.
• Keep a current list of all medications and substances.
• Record doses, dates, symptoms, sleep, and functional changes.
• Avoid planning major reductions immediately before travel, surgery, or major life stress.
• Ask family members to watch for pacing, confusion, unusual behavior, and severe insomnia.
• Discuss previous seizures, alcohol withdrawal, missed-dose reactions, and earlier taper attempts.
• Arrange appropriate treatment for the condition the benzodiazepine was originally prescribed to manage.

A successful taper is not a contest to reach zero as quickly as possible. The objective is to reduce medication-related risk without creating preventable withdrawal harm.

Conclusion: Name the Symptom Before Blaming the Patient

Akathisia during benzodiazepine tapering can be mistaken for anxiety, relapse, noncompliance, or emotional instability. Its defining clue is a distressing internal compulsion to move, often accompanied by pacing, rocking, repetitive leg movement, and an inability to remain still.

When these symptoms begin after a dose reduction, clinicians should consider withdrawal, review the complete medication history, assess safety, and determine whether the taper needs to be paused or slowed. Patients should not abruptly stop benzodiazepines or attempt to overpower severe symptoms without medical support.

Most importantly, descriptions such as “I cannot stop moving” should be taken literally. Recognizing akathisia early may prevent inappropriate medication changes, unnecessary psychiatric labeling, worsening withdrawal, and avoidable suffering.

Experiences From the Tapering Journey: Three Composite Scenarios

The following scenarios are fictional composites created from commonly reported clinical patterns. They do not describe identifiable patients and should not be treated as personalized medical advice.

Experience 1: “My anxiety came back”except it felt completely different

Rachel had taken a prescribed benzodiazepine nightly for several years. After reducing the dose, she expected a few restless nights. Instead, she began walking from the bedroom to the kitchen and back again for hours. When she sat down, tension seemed to build through her legs and torso until she had to stand.

She initially called the problem “extreme anxiety,” partly because anxiety was the only vocabulary she had been given. Yet she was not worrying about work, money, or family. Her thoughts were mostly focused on one urgent problem: how to escape the sensation inside her body.

Her family noticed constant rocking, foot tapping, and pacing. A detailed timeline showed that the symptoms had appeared shortly after a dose reduction. Rather than treating the reaction as proof that her original anxiety disorder had returned, her clinician reassessed the taper and reviewed other medications. The schedule was adjusted, and the movement symptoms were monitored separately from emotional worry.

The practical lesson was simple: “restlessness” needed a more precise description. Once Rachel explained that sitting still caused physical torment, the conversation changed.

Experience 2: A new medication complicated the detective work

Marcus began tapering a daytime benzodiazepine while also starting another psychiatric medication. Within two weeks, he became unable to sit through meetings. He shifted constantly, walked around the office, and slept only a few hours each night.

It would have been convenient to blame one medication and close the case before lunch. In reality, the timing suggested several possibilities. The benzodiazepine reduction could have caused withdrawal restlessness. The new medication could have produced akathisia. Sleep deprivation could also have amplified both problems.

His clinician reviewed every dose change rather than assuming the symptoms were psychological deterioration. Marcus was asked about inner restlessness, repetitive movement, worry, mood changes, substance use, and suicidal thoughts. That structured assessment helped separate akathisia-like symptoms from generalized anxiety and mania.

The experience illustrates why multiple medication changes at the same time can make adverse reactions difficult to identify. A careful timeline may be more useful than a dramatic guess.

Experience 3: The symptom appeared near the end, not the beginning

Elena tolerated the early stages of her taper reasonably well. Problems developed only after she reached a much lower dose. Each reduction represented a larger percentage of the remaining medication, even though the number of milligrams looked small on paper.

She developed severe insomnia, sensory sensitivity, and an urge to walk almost continuously. Because she had managed earlier reductions, she assumed she had suddenly become weak or overly focused on symptoms. That interpretation increased shame without improving anything.

Her clinician explained that the final portion of a benzodiazepine taper can be disproportionately difficult for some patients. The response was not treated as a moral failure. The taper was reassessed according to symptoms, function, and safety rather than an arbitrary completion date.

Elena also gave a family member permission to report concerning changes. This mattered because sleep deprivation and relentless restlessness made it harder for her to evaluate her own condition. They agreed in advance that suicidal thinking, hallucinations, confusion, or seizure activity would trigger emergency care.

These composite experiences share one theme: akathisia is easier to recognize when patients describe what their bodies are forcing them to do, clinicians examine the timing of medication changes, and everyone resists the urge to label every withdrawal symptom as “just anxiety.”